CMS is brokering outcomes-based agreements on behalf of Medicaid programs. Thirty-three states, along with Washington, D.C., ...

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

CMS has reached agreements with drug manufacturers to provide gene therapies to treat sickle cell disease to Medicaid recipients under a new outcomes-based model. A total of 33 states, including the ...

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

Columnist Oluwatosin Adesoye, a doctor, sorts through the difference between sickle cell anemia and sickle cell disease — and more.

Safi Biotherapeutics (Safi), a biotechnology company producing stem-cell derived, manufactured human red blood cell (mRBC) ...

The US regulator has launched a new national initiative to help Medicaid programs fund gene therapies for sickle cell disease ...

The Executive Director of the Ghana Foundation for Sickle Gene Action, Victoria Awo Twumasi, has appealed to President John Dramani Mahama to include full coverage of sickle cell disease (SCD) treatme ...

Panellists at a day’s conference to mark this year’s world sickle cell day have called for a fixed protocol for the treatment of sickle cell emergencies ...

The Centers for Medicare and Medicaid Services (CMS) has selected 35 participants for its new, voluntary Cell and Gene ...